Becton Dickinson (BDX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
$198.34+1.63%
Close 2026-10-29 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
Research Workspace
Put BDX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 5% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 19%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBDX's case rests on strong performance and robust cash-backed profits, supported by healthcare sector trends. Its U.S. manufacturing expansion adds a concrete growth investment. Revenue growth and the latest result are unavailable, so the growth trajectory remains unverified. BDX trades at 15× P/E versus a 30× peer median, while its own historical multiple is 14×. The market is pricing in more growth than the desk forecasts. A 17% next-quarter miss probability presents a specific earnings risk. Its unsteady management adds concern about frequent disruptive corporate change. Peer multiples imply a price about 6% below where it trades; our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. BDX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering BDX (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for BDX in the last 4 months.
Continue this research
Compare BDX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BDX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put BDX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Invest $2.5 billion in U.S. manufacturing capacity over 5 years
Significant investment aligns with U.S. manufacturing capacity objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $198.34
The last 12 months of price, then the range of analyst 12-month targets from today’s $198.34.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Invest $2.5 billion in U.S. manufacturing capacity over 5 years
Significant investment aligns with U.S. manufacturing capacity goals.
Successful trial enrollment supports new product development.
Advances: Advance New BD strategy focusing on growth platforms and margin expansion
Earnings beat supports growth strategy and margin expansion.
Advances: Spin-off Biosciences and Diagnostics
Positive outlook on business streamlining and returns.